Antiarrhythmics

Key Points

• Antiarrhythmics regulate cardiac conduction to control rate/rhythm or restore sinus rhythm.
• All antiarrhythmics carry proarrhythmic risk, so ECG and electrolyte monitoring are safety-critical.
• Class I sodium-channel blockers are subclassified as IA, IB, and IC with different proarrhythmic and indication profiles.
• Class IA agents (for example quinidine, procainamide) also block potassium channels, prolong QT, and can trigger torsades de pointes.
• Class III potassium-channel blockers (amiodarone, dronedarone, dofetilide, ibutilide, sotalol) require disciplined QTc-focused safety monitoring.
• Unclassified agents (atropine, digoxin, adenosine) use distinct AV-node or vagal mechanisms and require drug-specific administration safety.
• Sotalol initiation requires facility-level QTc monitoring; dose changes are required when QTc is prolonged.
• Amiodarone has severe toxicity risk (pulmonary, hepatic, bradyarrhythmic/conduction toxicity) and requires close follow-up.
• Adenosine for PSVT is given as rapid IV bolus with saline flush; brief transient asystole may occur.
• Lidocaine for dysrhythmia treatment is IV-only and requires formulation verification to avoid fatal wrong-route errors.
• In emergency dysrhythmia care, drug sequencing and dose-timing cues (adenosine, atropine, amiodarone, diltiazem, lidocaine, procainamide) must be protocol-driven and continuously monitored.

Pathophysiology

Arrhythmias include bradycardic, tachycardic, and irregular rhythms caused by altered impulse generation or conduction. Antiarrhythmics modify ion-channel flux and autonomic effects to suppress pathologic rhythms.

Because these agents alter conduction and refractoriness, they can also worsen rhythm instability. RN management requires focused pre-dose and post-dose surveillance of ECG pattern, blood pressure, heart rate, and electrolyte trends.

Classification

Class	Prototype Examples	Core Action
Class IA Sodium Channel Blockers	quinidine, procainamide	Moderate sodium-channel blockade plus potassium-channel blockade; prolong QT and refractory period
Class IB Sodium Channel Blockers	lidocaine, mexiletine	Mild sodium-channel blockade; mainly ventricular arrhythmia pathways
Class IC Sodium Channel Blockers	flecainide, propafenone	Strong sodium-channel blockade without potassium-channel blockade; marked conduction slowing
Class II Beta-Blockers	esmolol, metoprolol, atenolol, bisoprolol, propranolol, sotalol (also Class III activity)	Reduce SA automaticity, slow AV-node conduction, and decrease contractility for rate/rhythm control
Class III Potassium Channel Blockers	amiodarone, dronedarone, dofetilide, ibutilide, sotalol	Prolong repolarization and refractory period; class-wide QT-prolongation/torsades risk
Class IV Calcium Channel Blockers	diltiazem, verapamil	Slow AV-node calcium influx and ventricular response
Unclassified Antidysrhythmics	atropine, digoxin, adenosine	Heterogeneous mechanisms for bradycardia reversal, AV-node rate control, or AV-node reentry termination

Emergency Dosing Cues (Adult, Protocol-Dependent)

• Adenosine (SVT): 6 mg rapid IV bolus over about 1-2 seconds, then 12 mg rapid IV bolus if needed; 12 mg may be repeated once.
• Atropine (symptomatic bradycardia): 1 mg IV every 3-5 minutes; maximum total dose 3 mg.
• Amiodarone (unstable VT/VF infusion pathway): 150 mg IV over 10 minutes, then infusion pathway per protocol (for example 360 mg over 6 hours, then 540 mg over 18 hours).
• Diltiazem (AF with RVR or PSVT): 0.25 mg/kg IV over 2 minutes, then 0.35 mg/kg IV if inadequate response; infusion commonly starts around 10 mg/hour.
• Lidocaine (ventricular arrhythmia): 1-1.5 mg/kg IV bolus, then infusion (commonly 1-4 mg/min) when ordered.
• Procainamide (life-threatening ventricular arrhythmia): loading 10-17 mg/kg at 20-50 mg/min, then maintenance regimen as ordered.

Nursing Assessment

NCLEX Focus

Prioritize rhythm-safety monitoring: ECG trend, QT/QTc, electrolytes, perfusion, and contraindication screening before each dose decision.

• Assess baseline rhythm and hemodynamic status before administration.
• Monitor electrolytes relevant to proarrhythmia risk, especially potassium.
• For class IA pathways, monitor QT interval/torsades risk and avoid coadministration with strong QT-prolonging drugs.
• For quinidine, monitor for diarrhea-related electrolyte loss, hepatotoxicity, and thrombocytopenia.
• For procainamide, monitor for hypotension during infusion, blood dyscrasia risk, and lupus-like syndrome risk.
• For sotalol initiation/titration, monitor QTc about 2-4 hours after each early dose and evaluate renal function for dose adjustment.
• For sotalol, treat QTc greater than about 500 msec as a dosing-safety escalation threshold per protocol.
• For class III pathways overall, complete medication reconciliation for additive QT-prolonging drugs before initiation.
• For dofetilide and sotalol, verify baseline QTc and renal function before first dose; these agents require monitored initiation with resuscitation capability.
• For ibutilide cardioversion, maintain continuous ECG and postdose observation (commonly at least 4 hours) for torsades surveillance.
• For atropine bradycardia treatment, administer as rapid IV push because slow administration can produce paradoxical bradycardia.
• Atropine has limited/no therapeutic bradycardia response in heart-transplant recipients because vagal innervation is absent.
• In ACLS symptomatic-bradycardia pathways, atropine has no absolute contraindication in the emergency setting.
• For class II beta-blocker antiarrhythmic use, check pre-dose heart rate and blood pressure and hold/escalate for severe bradycardia or cardiogenic-shock patterns.
• Emphasize no abrupt discontinuation of beta-blockers because rebound tachyarrhythmia, angina, or ischemic events can occur.
• For amiodarone, assess hepatic, pulmonary, thyroid, ocular, and conduction-risk factors and reconcile interacting medications.
• For amiodarone and dronedarone, review CYP/P-glycoprotein interaction burden (for example digoxin, warfarin, selected statins, and selected calcium-channel blockers).
• For diltiazem/verapamil pathways, assess for hypotension, AV block, bradycardia, and heart-failure worsening risk.
• For adenosine administration, prepare for transient conduction pause/asystole and continuous ECG response monitoring.
• For adenosine, screen for methylxanthine/caffeine exposure and dipyridamole/carbamazepine interactions that can alter response.
• For lidocaine infusions, monitor for CNS toxicity progression (sedation, twitching, seizure, respiratory depression).
• For flecainide and propafenone, screen for structural heart disease (for example prior MI or heart failure) before use.

Nursing Interventions

• Use continuous or intermittent ECG monitoring based on medication phase and acuity.
• Hold/escalate when contraindication patterns are present (for example severe bradycardia, higher-grade block without pacing support, hypotension, severe bronchospasm risk where applicable).
• Verify exact formulation/route before administration for look-alike medications; never use lidocaine-with-epinephrine products as antidysrhythmic therapy.
• For adenosine PSVT treatment, place client supine and administer rapid IV bolus followed by saline flush per protocol.
• Avoid diltiazem in ventricular tachycardia and do not coadminister with IV beta-blockers because severe bradycardia/heart block can occur.
• Reinforce adherence and avoid unsupervised dose doubling after missed doses.
• Teach pulse/BP self-monitoring parameters and urgent reporting for syncope, fast irregular pulse, or worsening dizziness.
• Teach orthostatic precautions and photosensitivity precautions where relevant.
• Counsel to avoid grapefruit and sour orange products with susceptible antiarrhythmic pathways.
• Teach class I clients to report severe diarrhea, jaundice, fever, or sore throat promptly.
• Teach class III clients to seek emergency care for torsades-warning symptoms (palpitations, presyncope/syncope, acute dizziness).
• Prepare clients receiving adenosine for expected brief flushing/discomfort and possible transient asystole sensation to reduce panic.

Proarrhythmia Risk

Antiarrhythmics can worsen or induce dysrhythmia; initiation and dose changes require disciplined ECG-guided reassessment.

Nonlife-Threatening Arrhythmia Caution

In selected trials, antiarrhythmic use for nonlife-threatening arrhythmias increased mortality risk versus placebo.

Pharmacology

Drug	Typical Clinical Use	Key RN Considerations
Quinidine	AF/flutter cardioversion and sinus-rhythm maintenance; recurrent ventricular arrhythmia suppression	Boxed mortality warning context, QT prolongation/torsades risk, diarrhea-induced electrolyte loss, thrombocytopenia/hepatotoxicity surveillance, avoid grapefruit/sour orange
Procainamide	Life-threatening ventricular arrhythmias; selected off-label atrial arrhythmia use	Boxed warning context (blood dyscrasia/lupus-like risk), QT prolongation risk, infusion-rate hypotension risk, ECG/CBC and procainamide-NAPA level monitoring
Lidocaine	Acute ventricular arrhythmia treatment, including ACLS ventricular-arrest pathways	IV-only for arrhythmia use, continuous ECG monitoring, CNS-toxicity surveillance, never substitute topical or epinephrine-combination formulations
Mexiletine	Long-term oral management of ventricular arrhythmias	Class IB oral follow-on pathway; monitor rhythm response and liver-toxicity cues (for example jaundice)
Flecainide	Paroxysmal symptomatic SVT/AF/flutter and selected life-threatening ventricular tachyarrhythmia use	Risk of 1:1 AV conduction in AF/flutter and hemodynamic collapse; monitor ECG closely; avoid in structural heart disease
Propafenone	Life-threatening ventricular arrhythmias; recurrence-delay in paroxysmal AF/flutter without structural heart disease	Contraindicated in structural heart disease; monitor proarrhythmia risk; selected supervised “pill-in-the-pocket” strategy may be used in recurrent symptomatic AF
Esmolol	Rapid IV control of sinus tachycardia/SVT/AF-flutter and perioperative tachycardia pathways	Very short half-life with titratable infusion; frequent BP and rhythm reassessment; monitor for vesicant extravasation injury
Metoprolol	AF/flutter and other supraventricular-rate control pathways; selected ventricular-arrhythmia support contexts	Distinguish tartrate vs succinate forms and IV vs oral dosing schedules; monitor bradycardia, hypotension, AV block, and heart-failure decompensation risk
Sotalol	Symptomatic AF/flutter and severe ventricular-arrhythmia pathways	Baseline QTc should be acceptable before start (commonly avoid when >450 msec), inpatient monitored initiation, QTc >500 msec dose-interval extension or discontinuation, renal-dose constraints
Amiodarone	Life-threatening recurrent ventricular arrhythmias refractory/intolerant to alternatives	Very long half-life with prolonged residual effect after discontinuation, boxed pulmonary/hepatic/arrhythmia warnings, baseline and periodic ECG/PFT-chest imaging/LFT-thyroid-ocular monitoring, major interaction burden (for example digoxin/warfarin/statins)
Dronedarone	Paroxysmal or persistent AF management in selected patients	Contraindicated in symptomatic HF and nonconvertible/permanent AF patterns; interaction burden via CYP pathways; hazardous handling and pregnancy contraindication considerations
Dofetilide	AF/flutter conversion and sinus-rhythm maintenance	Pure class III agent with high torsades risk; initiation requires monitored setting (minimum about 3 days), baseline QTc and renal-function screening, QTc-based dose adjustment/discontinuation thresholds
Ibutilide	Recent-onset AF/flutter pharmacologic cardioversion	IV-only short-course conversion pathway, high torsades risk, continuous ECG plus postdose observation (at least 4 hours), anticoagulation planning needed before cardioversion in prolonged AF duration
Diltiazem/Verapamil (Class IV antiarrhythmic use)	AF/flutter/SVT rate-control pathways; also angina/HTN contexts	Monitor bradycardia/hypotension/AV block/HF worsening, avoid in hypotension or acute MI/high-grade block/sick-sinus without pacing, and use caution with beta-blockers and simvastatin co-therapy
Atropine	Symptomatic bradycardia reversal	Rapid IV dosing required, monitor for anticholinergic burden/tachycardia, and do not expect effect in denervated transplanted hearts
Digoxin	AF/flutter ventricular-rate control (especially selected HF with reduced EF coexistence)	Narrow therapeutic index, monitor renal function and apical pulse; toxicity risk rises with electrolyte imbalance; digoxin immune fab for severe toxicity
Adenosine	Paroxysmal supraventricular tachycardia termination	Give as rapid IV push close to client with immediate saline flush; brief asystole/flushing/sense-of-doom may occur; continuous ECG/resuscitation readiness required

Clinical Judgment Application

Clinical Scenario

A client with persistent tachyarrhythmia is newly started on sotalol during monitored inpatient initiation.

• Recognize Cues: Baseline rhythm instability, renal-function dependence, and QTc-sensitive medication profile.
• Analyze Cues: Early-dose period carries elevated proarrhythmia risk if QTc prolongs.
• Prioritize Hypotheses: Highest priority is drug-induced dysrhythmia prevention while achieving rhythm control.
• Generate Solutions: Schedule protocol ECG/QTc checks, electrolyte surveillance, and dose-adjustment readiness.
• Take Action: Administer as ordered with timed reassessment and immediate escalation for QTc or perfusion deterioration.
• Evaluate Outcomes: Rhythm control improves without torsades, severe bradycardia, or hemodynamic decline.

Related Concepts

• systematic-ecg-interpretation-and-dysrhythmia-triage - ECG interpretation and emergency rhythm triage framework.
• beta-blockers - Class II overlap and bradycardia/hypotension monitoring.
• calcium-channel-blockers - Class IV overlap for AV-node rate control.
• heart-failure - Comorbid HF increases antiarrhythmic risk complexity.
• anticoagulants - Common co-therapy in atrial-fibrillation pathways.

Self-Check

1. Why must antiarrhythmic therapy decisions be linked to ECG and electrolyte trends?
2. Which safety checks are priority during sotalol initiation?
3. What bedside event is expected briefly after adenosine rapid IV administration?